Logo image of 1VKTX.MI

VIKING THERAPEUTICS INC (1VKTX.MI) Stock Fundamental Analysis

BIT:1VKTX - Euronext Milan - US92686J1060 - Common Stock - Currency: EUR

27.25  +0.5 (+1.85%)

Fundamental Rating

3

1VKTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 67 industry peers in the Biotechnology industry. While 1VKTX has a great health rating, there are worries on its profitability. 1VKTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

1VKTX had negative earnings in the past year.
In the past year 1VKTX has reported a negative cash flow from operations.
In the past 5 years 1VKTX always reported negative net income.
In the past 5 years 1VKTX always reported negative operating cash flow.
1VKTX.MI Yearly Net Income VS EBIT VS OCF VS FCF1VKTX.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

1VKTX has a Return On Assets of -20.72%. This is comparable to the rest of the industry: 1VKTX outperforms 58.21% of its industry peers.
1VKTX has a better Return On Equity (-21.57%) than 64.18% of its industry peers.
Industry RankSector Rank
ROA -20.72%
ROE -21.57%
ROIC N/A
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
1VKTX.MI Yearly ROA, ROE, ROIC1VKTX.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

1VKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
1VKTX.MI Yearly Profit, Operating, Gross Margins1VKTX.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for 1VKTX has been increased compared to 1 year ago.
1VKTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for 1VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
1VKTX.MI Yearly Shares Outstanding1VKTX.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
1VKTX.MI Yearly Total Debt VS Total Assets1VKTX.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

1VKTX has an Altman-Z score of 65.76. This indicates that 1VKTX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 65.76, 1VKTX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
There is no outstanding debt for 1VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 65.76
ROIC/WACCN/A
WACCN/A
1VKTX.MI Yearly LT Debt VS Equity VS FCF1VKTX.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

1VKTX has a Current Ratio of 25.86. This indicates that 1VKTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 25.86, 1VKTX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
A Quick Ratio of 25.86 indicates that 1VKTX has no problem at all paying its short term obligations.
The Quick ratio of 1VKTX (25.86) is better than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 25.86
Quick Ratio 25.86
1VKTX.MI Yearly Current Assets VS Current Liabilites1VKTX.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

0

3. Growth

3.1 Past

1VKTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -62.77%.
EPS 1Y (TTM)-62.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

1VKTX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.15% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-92.69%
EPS Next 2Y-61.84%
EPS Next 3Y-44.88%
EPS Next 5Y-1.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
1VKTX.MI Yearly Revenue VS Estimates1VKTX.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
1VKTX.MI Yearly EPS VS Estimates1VKTX.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 1VKTX. In the last year negative earnings were reported.
Also next year 1VKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1VKTX.MI Price Earnings VS Forward Price Earnings1VKTX.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1VKTX.MI Per share data1VKTX.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

1VKTX's earnings are expected to decrease with -44.88% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.84%
EPS Next 3Y-44.88%

More info and screens

0

5. Dividend

5.1 Amount

1VKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIKING THERAPEUTICS INC

BIT:1VKTX (7/22/2025, 7:00:00 PM)

27.25

+0.5 (+1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-23 2025-07-23/amc
Earnings (Next)10-21 2025-10-21/amc
Inst Owners69.61%
Inst Owner ChangeN/A
Ins Owners2.12%
Ins Owner ChangeN/A
Market Cap3.06B
Analysts84.8
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.64%
Min EPS beat(2)-27.37%
Max EPS beat(2)-23.91%
EPS beat(4)1
Avg EPS beat(4)-12.66%
Min EPS beat(4)-27.37%
Max EPS beat(4)14.36%
EPS beat(8)4
Avg EPS beat(8)-1.83%
EPS beat(12)6
Avg EPS beat(12)-1.06%
EPS beat(16)8
Avg EPS beat(16)0.69%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.51
P/tB 4.51
EV/EBITDA N/A
EPS(TTM)-1.31
EYN/A
EPS(NY)-2.23
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS6.04
TBVpS6.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.72%
ROE -21.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.86
Quick Ratio 25.86
Altman-Z 65.76
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190%
EPS Next Y-92.69%
EPS Next 2Y-61.84%
EPS Next 3Y-44.88%
EPS Next 5Y-1.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-70.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-50.9%
EBIT Next 3Y-36.69%
EBIT Next 5Y-19.56%
FCF growth 1Y-152.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-152.08%
OCF growth 3YN/A
OCF growth 5YN/A